MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027. BioNTech’s disciplined approach to capital allocation and strong financial position enables this authorization.
BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The Program is designed to enhance capital efficiency, support long-term value creation and maintain financial flexibility alongside BioNTech’s objective to become a multi-product company by 2030.
The commencement, timing and total amount of ADS repurchases will depend upon market conditions and may be made in open market purchases from time to time, with a focus on price efficient repurchases to ensure prudent deployment of capital. BioNTech expects to fund the Program using its existing cash resources.
“We are confident in the Company’s long-term growth prospects, and this share repurchase program is consistent with our capital allocation strategy and our commitment to sustainable value creation for our shareholders,” said Ramón Zapata, Chief Financial Officer at BioNTech. “At the same time, our disciplined approach to capital deployment enables us to maintain the financial strength necessary to advance our innovative pipeline and aim for self-sustaining growth in the years ahead.”
The Program has been designed to operate within the safe harbor provided by Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the affirmative defense provided by Rule 10b5-1 of the Exchange Act.
